According to Zacks, “BioVie Inc. engages in developing drug therapies for liver disease. The company’s product candidate includes BIV201, which are in clinical stage. BioVie Inc. is based in SANTA MONICA, CA. “
BIVI has been the subject of several other research reports. B. Riley reduced their target price on shares of BioVie from $27.00 to $18.00 in a research note on Monday, January 24th. Oppenheimer started coverage on shares of BioVie in a research note on Monday, March 14th. They set an “outperform” rating and a $9.00 price target for the company.
Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in shares of BioVie by 90.3% in the third quarter. Renaissance Technologies LLC now owns 53,100 shares of the company’s stock valued at $355,000 after purchasing an additional 25,200 shares in the last quarter. swisspartners Ltd. grew its holdings in BioVie by 45.0% during the 3rd quarter. swisspartners Ltd. now owns 80,521 shares of the company’s stock worth $542,000 after acquiring an additional 25,000 shares during the period. Long Focus Capital Management LLC acquired a new stake in BioVie during the 4th quarter worth $90,000. State Street Corp acquired a new position in shares of BioVie in the 4th quarter valued at $67,000. Finally, Susquehanna International Group LLP acquired a new position in shares of BioVie in the 4th quarter valued at $48,000. Institutional investors own 6.62% of the company’s stock.
About BioVie (Get Rating)
BioVie Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease.
- Get a free copy of the StockNews.com research report on BioVie (BIVI)
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.